Key information for investors | Gentian Diagnostics AS
medical, diagnostics, immunoassays, assays, in vitro diagnostics, IVD products, avian antibodies, antibodies, clinical chemistry, diagnostic tests, biotechnology
15612
page-template,page-template-full_width,page-template-full_width-php,page,page-id-15612,page-child,parent-pageid-15340,ajax_fade,page_not_loaded,,qode-content-sidebar-responsive,qode-child-theme-ver-1.0.0,qode-theme-ver-14.2,qode-theme-bridge,wpb-js-composer js-comp-ver-6.0.3,vc_responsive
 

Key information

Gentian Diagnostics AS serves the global market with sensitive diagnostic tests. Current and pipeline products contribute to improved diagnostics and cost reductions in treatment of kidneys, inflammation, cardiovascular diseases, cancer and viral infections.

 

On 14th December, 2016, Gentian Diagnostics AS was admitted to the Oslo Stock Exchange list ‘Merkur Market’ under the ticker GENT-ME.

 

Find more information about the Gentian Share on Oslo Børs.

 

Learn more about Gentian Diagnostics AS here.

Financial Calendar 2019

9TH MAY – ANNUAL REPORT

9TH MAY – QUARTERLY REPORT Q1

28TH MAY – ANNUAL GENERAL MEETING

15TH AUG – HALF–YEARLY REPORT

7TH NOV – QUARTERLY REPORT – Q3

28th of May 2019: Annual General Meeting

Annual General Meeting for Gentian Diagnostics AS was hold on the 28th of May 2019.

For more information, please see the notice and documents below:

Presentations

Historical

Look at our historical archive to find financial reports and data from 2018, 2017 and 2016.